Adynxx Seeks to Silence Acute, Prevent Chronic Pain
Fewer than five years after Adynxx Inc. was formed on the basis of "a great idea," the company disclosed that it moved lead compound AYX1 into the clinic, completing enrollment in a Phase I safety study in postoperative pain.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter